Open company graph database — free web & API
Login

Restore Vision Inc.

株式会社レストアビジョン
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
1
§01

Basic information

BASIC
Head office
1-17-1 Toranomon, Minato-ku, Tokyo 105-6415, Japan, Toranomon Hills Business Tower 15F
Chief executive
Yusaku Katada
Capital
Employees (non-consolidated)
Employees (consolidated)
Start date
2016-11-14
End date
§02

Websites

1 DOMAINS
§03

Business

3
Research and clinical development of gene therapy drugsA biotech venture developing proprietary drugs for regenerative medicine and expanding GCTP-compliant CDMO servicesResearch and development of regenerative medicine products
§04

Related companies

1 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Keio University
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

4 EVENTS

Established: November 14, 2016Sources

Dr. Hitoshi Kawamura PhD has been an R&D advisor to Restore Vision since 2021.Sources

Raised 1.3 billion yen in a pre-Series B round in April 2026. Investors include Higo Bank Capital, Kyoto University Innovation Capital, JIC Venture Growth Investments, Japan Science and Technology Agency, Remiges Ventures, Astellas Venture Management, Ajinomoto, Shionogi Pharmaceutical, Japan Venture Capital.Sources

Secured funding from Kyoto Capital Partners in a pre-Series B round in June 2026.Sources

§07

News

56 ARTICLES

The Nobel Prize and Optogenetics ResearchSources

The 2026 Nobel Prize in Physiology or Medicine was awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for their discoveries concerning light-gated ion channels and optogenetics. This article introduces the scientific background of the award-winning research, rhodopsin research in Japan, and the history of collaboration between Restore Vision and domestic research institutions. The prize was not awarded for work on Restore Vision or chimeric rhodopsins.

Selected for AMED Regenerative Medicine and Gene Therapy Technology Development ProgramSources

Restore Vision Inc. was selected as the lead organization for AMED’s FY2026 program to develop foundational technologies for the industrialization of regenerative medicine and gene therapy. The company plans to further accelerate development.

Restore Vision and Forge Biologics Partner on AAV TherapeuticsSources

Restore Vision Inc. and Forge Biologics announced a partnership to develop adeno-associated virus (AAV) therapeutics and provide cGMP manufacturing services. The collaboration aims to accelerate production of AAV-based gene therapies. Further details are available in Forge Biologics’ press release.

Restore Vision and Forge Biologics Partner on AAV Development and cGMP ManufacturingSources

Restore Vision Inc. announced a partnership with Forge Biologics on AAV development and cGMP manufacturing. The two companies plan to jointly develop and manufacture AAV vectors. See Forge Biologics’ press release for details.

Restore Vision Raises Additional Pre-Series B FundingSources

Restore Vision Inc. raised additional funding in its Pre-Series B round from Kyoto Capital Partners. The funds will support global development of lead candidate RV-001, R&D for a second pipeline, stronger corporate management, and hiring. The additional investment is expected to bring the total Pre-Series B funding to more than ¥5.8 billion.

Interim Results Announced for RV-001Sources

Restore Vision announced interim first-in-human results through day 168 from a Phase I/II trial of RV-001, a GPCR-based optogenetic gene therapy. Results from two dosing cohorts with advanced retinitis pigmentosa were presented at Eyecelerator and the Retinal Therapeutics Innovation Summit. No dose-limiting toxicities or drug-related serious adverse events were reported after a single intravitreal injection in either the low- or high-dose cohort (n=3 per cohort). Patients in the high-dose cohort began with no light perception.

Interim RV-001 Trial Results Show Improved Light Perception and Confirm SafetySources

Interim Phase I/II trial results through day 168 are scheduled to be announced. No dose-limiting toxicities or serious adverse events have been reported in either the low- or high-dose cohort after a single intravitreal injection. The high-dose cohort showed improved light perception, with consistent dose-dependent improvements in visual acuity, FST, and functional vision assessments.

Restore Vision Secures ¥1.3 Billion in Pre-Series B FundingSources

Restore Vision Inc. announced ¥1.3 billion in pre-Series B financing through J-KISS-type stock acquisition rights, with five existing and four new investors participating. This brings cumulative equity financing to approximately ¥3.5 billion. Including grants secured to date, total funding exceeds ¥5.8 billion.

Restore Vision Raises ¥1.3 Billion in Pre-Series B, Total Funding Exceeds ¥5.8 BillionSources

Restore Vision Inc. raised ¥1.3 billion through J-KISS-type stock acquisition rights, bringing total funding including grants to more than ¥5.8 billion. The funds will mainly support global development of lead candidate RV-001, research and development, and hiring. The company was also awarded ¥2.1 billion under AMED’s drug discovery startup program and plans to receive up to an additional ¥4.5 billion in grants.

Professor Kandori Receives Uehara Prize for Chimera Rhodopsin InventionSources

Professor Hideki Kandori, an advisor to Restore Vision and inventor of chimera rhodopsin, the core technology of lead program RV-001, received the 2024 Uehara Prize. The award recognizes outstanding achievements in life sciences. A commemorative lecture held on March 11, 2025, was released following the award.

§08

Public records

GOV
National Tax Agency basic information8010401128258
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社レストアビジョン
Trade name (kana)
レストアビジョン
Name in English
Corporation type
301
Address
〒105-0001 東京都港区虎ノ門1丁目17番1号虎ノ門ヒルズビジネスタワー15階
Postal code
1050001
Prefecture code
13
City code
103
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2016-11-15
Update date
2021-08-23
Change date
2021-08-19
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
2344629
METI gBizINFO8010401128258
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
8010401128258
Trade name
株式会社レストアビジョン
Trade name (kana)
レストアビジョン
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都港区虎ノ門1丁目17番1号虎ノ門ヒルズビジネスタワー15階
Postal code
1050001
Prefecture
東京都
Prefecture code
13
City or district
港区
City code
103
Street address
虎ノ門1丁目17番1号虎ノ門ヒルズビジネスタワー15階
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
Capital
Employees
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2021-08-23
Key information
8010401128258
§09

Sources & updates

SOURCES
↑